Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Shots:Sandoz agreed to acquire Just-Evotec Biologics EU SAS in Toulouse , including its manufacturing site to expand in-house continuous manufacturing for biosimilars, supporting its strategy to capture a projected ~$300B biosimilars market over the next decadeSandoz will buy 100% of Just-Evotec Biologics SAS and secure a perpetual license for its continuous manufacturing platform…

ByDipanshu DixitNovember 5, 2025

NEWS

Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management

Shots:Zealand Pharma & Roche will develop & market petrelintide & its products incl. petrelintide + CT-388 (Roche’s asset) in the US & EU for weight loss, with Roche obtaining exclusive marketing rights in the rest of the world Zealand will handle ~50% marketing in the US & EU with opt-in/out rights under specific…

ByRidhi RastogiMarch 12, 2025

VIEWPOINTS

Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets

Shots:Matthew spoke about Immunome’s collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery EngineHe also talked about how the partnership with AbbVie can support Immunome’s strategy to maximize the new drug discovery potential of its Discovery Engine…

BySenior EditorMay 8, 2023

Sandoz Acquires Just-Evotec Biologics EU SAS in Toulouse to Strengthen its In-House Biosimilar Capabilities

Zealand Pharma and Roche enter a ~$5.3B Deal to Co-Develop and Commercialize Petrelintide for Weight Management

Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets

Contact US

OUR INFORMATION

FOLLOW US